You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

77 Results
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Palliative
Jun 2019
Drug
Other Name(s): Mozobil®
Jun 2019
Drug
Other Name(s): Xofigo®
Jun 2019
Regimen
Cancer Type:
Gynecologic, 
Cervix, 
Endometrial, 
Ovary
Intent: Palliative, Adjuvant
Jun 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant, Adjuvant
Jun 2019
Regimen
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Rare Diseases, 
Sarcoma
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jun 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel
Aug 2025
Drug
Other Name(s): Padcev®
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria
Exceptional Access Program
    venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria
Aug 2025

Pages